Cart 2

Anti-CCN3 / NOV (IGFBP9) antibody

Cat.#: 103821

Size:

Special Price 145.0 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-CCN3 / NOV (IGFBP9) antibody
  • Documents
  • Description
    Rabbit polyclonal to CCN3 / NOV (IGFBP9)
  • Tested applications
    ELISA, WB, IHC-P
  • Species reactivity
    Human CCN3 / NOV / IGFBP9
  • Alternative names
    IGFBP-9 antibody; Nov antibody; IGF-binding protein 9 antibody; IGFBP9 antibody; NOV antibody; CCN3 antibody; NOVh antibody; IBP-9 antibody; IGFBP9 antibody; IGFBP-9 antibody; CCN3 antibody; C130088N23Rik antibody; C130088N23Rik antibody; CCN3 antibody; CCN3 antibody; IBP-9 antibody
  • Immunogen
    Human CCN3 / NOV (IGFBP9) (His Tag) recombinant protein
  • Isotype
    Rabbit IgG
  • Preparation
    Produced in rabbits immunized with purified, recombinant Human CCN3 / NOV / IGFBP9 (rh CCN3 / NOV / IGFBP9; NP_002505.1; Met 1-Met 357). CCN3 / NOV / IGFBP9 specific IgG was purified by Human CCN3 / NOV / IGFBP9 affinity chromatography.
  • Clonality
    Polyclonal
  • Formulation
    0.2 μm filtered solution in PBS with 5% trehalose
  • Storage instructions
    This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
    Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
  • Applications

    WB: 10-20 μg/mL

    ELISA: 0.1-0.2 μg/mL

    This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human NOV. The detection limit for Human NOV is approximately 0.00245 ng/well.

    IHC-P: 2-5 μg/mL

  • Validations

    CCN3 / NOV / IGFBP9 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CCN3 / NOV / IGFBP9 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    Immunochemical staining of human NOV in human brain (from 2 donors) with rabbit polyclonal antibody (2 µg/mL, formalin-fixed paraffin embedded sections).

    CCN3 / NOV / IGFBP9 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    CCN3 / NOV / IGFBP9 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry

    Immunochemical staining of human NOV in human brain with rabbit polyclonal antibody (2 µg/mL, formalin-fixed paraffin embedded sections). The left panel: tissue incubated with primary antibody; The right panel: tissue incubated with the mixture of primary antibody and antigen (recombinant protein).

    CCN3 / NOV / IGFBP9 Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot

    CCN3 / NOV / IGFBP9 Antibody, Rabbit PAb, Antigen Affinity Purified, Western blot

  • Background
    Protein NOV homolog, also known as Nephroblastoma-overexpressed gene protein homolog, NOV, and CCN3, is a putative ligand for integrin receptors, is tightly associated with the extracellular matrix and mediates diverse cellular functions, including cell adhesion and proliferation. CCN3 has been shown to negatively regulate growth although it promotes migration in a cell type-specific manner. This secreted protein belongs to the CCN family, and its expression was observed in a broad variety of tissues from the early stage of development , and altered expression of CCN3 has been observed in a variety of tumors, including hepatocellular carcinomas, Wilm's tumors, Ewing's sarcomas, gliomas, rhabdomyosarcomas, and adrenocortical carcinomas. Mature CCN3 protein has five distinct modules and truncated protein variants with altered function are found in many cancers. CCN3 acts through the core stem cell signalling pathways including Notch and Bone Morphogenic Protein, connecting CCN3 with the modulation of self-renewal and maturation of a number of cell lineages including hematopoietic, osteogenic and chondrogenic. CCN3 may affect the extracellular environment of the niche for hematopoietic stem cells. CCN3 has emerged as a key player in stem cell regulation, hematopoiesis and a crucial component within the bone marrow microenvironment.
  • References
    • Manara MC, et al. (2002) The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol. 160(3): 849-59.
    • Lin CG, et al. (2003) CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 278(26): 24200-8.
    • Vallacchi V, et al. (2009) CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 68(3): 715-23.
    • Sin WC, et al. (2009) Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization. J Biol Chem. 284(43): 29935-44.
    • McCallum L, et al. (2009) CCN3--a key regulator of the hematopoietic compartment. Blood Rev. 23(2): 79-85.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"